Bradykinin, angiotensin-(1-7), and ACE inhibitors: How do they interact?

International Journal of Biochemistry and Cell Biology

Volumn 35, Issue 6, 2003, Pages 792-801

  Tom, Beril ^a   Dendorfer, Andreas ^b   Jan Danser, A H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

ACE; Angiotensin (1 7); B 2 receptor; Bradykinin; Neutral endopeptidase

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN I; ANGIOTENSIN[1-7]; BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

DRUG EFFECT; DRUG POTENTIATION; EVALUATION; HEART FAILURE; HYPERTENSION; MOLECULAR INTERACTION; PROTEIN HYDROLYSIS; PROTEIN METABOLISM; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0037409325     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(02)00273-X     Document Type: Short Survey

References (80)

1. Abbas A., Gorelik G., Carbini L.A., Scicli A.G. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 30:1997;217-221.
2. 1 -receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature. 407:2000;94-98.
3. Auch-Schwelk W., Bossaller C., Claus M., Graf K., Gräfe M., Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovascular Research. 27:1993;312-317.
4. Baumgarten C.R., Linz W., Kunkel G., Schölkens B.A., Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. British Journal of Pharmacology. 108:1993;293-295.
5. Benter I.F., Ferrario C.M., Morris M., Diz D.I. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. American Journal of Physiology. 269:1995;H313-H319.
6. 2 kinin receptor within the plasma membrane of native endothelial cells. Circulation. 99:1999;2034-2040.
7. Blais C., Drapeau G., Raymond P., Lamontagne D., Gervais N., Venneman I., Adam A. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. American Journal of Physiology. 273:1997;H2263-H2271.
8. 2 receptor from human fibroblasts. The Journal of Biological Chemistry. 271:1996;32366-32374.
9. Bönner G., Preis S., Schunk U., Toussaint C., Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. Journal of Cardiovascular Pharmacology. 15:1990;S46-S56.
10. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 27:1996;523-528.
11. Campbell D.J., Duncan A.M., Kladis A. Angiotensin-converting enzyme inhibition modifies angiotensin but not kinin peptide levels in human atrial tissue. Hypertension. 34:1999;171-175.
12. Campbell D.J., Kladis A., Duncan A.M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 21:1993a;155-165.
13. Campbell D.J., Kladis A., Duncan A.M. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension. 22:1993b;513-522.
14. Chappell M.C., Pirro N.T., Sykes A., Ferrario C.M. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension. 31:1998;362-367.
15. Cyr M., Lepage Y., Blais C., Gervais N., Cugno M., Rouleau J.L., Adam A. Bradykinin and des-Arg(9)-bradykinin metabolic pathways and kinetics of activation of human plasma. American Journal of Physiology. 281:2001;H275-H283.
16. Danser A.H.J., de Vries R., Schoemaker R.G., Saxena P.R. Bradykinin-induced release of nitric oxide by the isolated perfused rat heart: importance of preformed pools of nitric oxide-containing factors. Journal of Hypertension. 16:1998;239-244.
17. Danser A.H.J., Tom B., de Vries R., Saxena P.R. L-NAME resistant bradykinin-induced relaxation in porcine coronary arteris is NO-dependent: effect of ACE inhibition. British Journal of Pharmacology. 131:2000;195-202.
18. Davie A.P., McMurray J.J. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension. 34:1999;457-460.
19. Deddish P.A., Marcic B., Jackman H.L., Wang H.Z., Skidgel R.A., Erdös E.G. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension. 31:1998;912-917.
20. 2 receptor. Hypertension. 39:2002;619-623.
21. Dendorfer A., Reissmann S., Wolfrum S., Raasch W., Dominiak P. Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation. Hypertension. 38:2001;142-146.
22. Dendorfer A., Wolfrum S., Schafer U., Stewart J.M., Inamura N., Dominiak P. Potentiation of the vascular response to kinins by inhibition of myocardial kininases. Hypertension. 35:2000;32-37.
23. Dendorfer A., Wolfrum S., Wagemann M., Qadri F., Dominiak P. Pathways of bradykinin degradation in blood and plasma of normotensive and hypertensive rats. American Journal of Physiology. 280:2001;H2182-H2188.
24. Dendorfer A., Wolfrum S., Wellhoner P., Korsman K., Dominiak P. Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. British Journal of Pharmacology. 122:1997;1179-1187.
25. Duka I., Kintsurashvili E., Gavras I., Johns C., Bresnahan M., Gavras H. Vasoactive potential of the B(1) bradykinin receptor in normotension and hypertension. Circulation Research. 88:2001;275-281.
26. Duncan A.M., Kladis A., Jennings G.L., Dart A.M., Esler M., Campbell D.J. Kinins in humans. American Journal of Physiology. 278:2000;R897-R904.
27. d'Uscio L.V., Quaschning T., Burnett J.C., Lüscher T.F. Vasopeptidase inhibition prevents endothelial dysfunction of resistance arteries in salt-sensitive hypertension in comparison with single ACE inhibition. Hypertension. 37:2001;28-33.
28. Erdös E.G. Kinins, the long march - a personal view. Cardiovascular Research. 54:2002;485-491.
29. Farquharson C.A., Struthers A.D. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. Journal of the American College of Cardiology. 39:2002;767-775.
30. Fernandes L., Fortes Z.B., Nigro D., Tostes R.C., Santos R.A.S., Catelli de Carvalho M.H. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension. 37:2001;703-709.
31. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension. 30:1997;535-541.
32. Ferreira A.J., Santos R.A.S., Almeida A.P. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension. 38:2001;665-668.
33. 2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin. Canadian Journal of Physiology and Pharmacology. 80:2002;153-163.
34. Gorelik G., Carbini L.A., Scicli A.G. Angiotensin-(1-7) induces bradykinin-mediated relaxation in porcine coronary artery. Journal of Pharmacology and Experimental Therapy. 286:1998;403-410.
35. Hecker M., Pörsti I., Bara A.T., Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. British Journal of Pharmacology. 111:1994;238-244.
36. 1 receptor. The Journal of Biological Chemistry. 277:2002;16847-16852.
37. Ishigai Y., Mori T., Ikeda T., Fukuzawa A., Shibano T. Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. American Journal of Physiology. 273:1997;H2659-H2663.
38. Iyer S.N., Averill D.B., Chappell M.C., Yamada K., Allred A.J., Ferrario C.M. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension. 36:2000;417-422.
39. Iyer S.N., Chappell M.C., Averill D.B., Diz D.I., Ferrario C.M. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension. 31:1998;699-705.
40. Iyer S.N., Ferrario C.M., Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension. 31:1998;356-361.
41. Kokkonen J.O., Lindstedt K.A., Kuoppala A., Kovanen P.T. Kinin-degrading pathways in the human heart. Trends in Cardiovascular Medicine. 10:2000;42-45.
42. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., van Gilst W.H. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 105:2002;1548-1550.
43. Maassen van den Brink A., de Vries R., Saxena P.R., Schalekamp M.A.D.H., Danser A.H.J. Vasoconstriction by in situ formed angiotensin II: role of ACE and chymase. Cardiovascular Research. 44:1999;407-415.
44. Mahon J.M., Carr R.D., Nicol A.K., Henderson I.W. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. Journal of Hypertension. 12:1994;1377-1381.
45. 1 receptors for kinins. Pharmacological Reviews. 50:1998;357-386.
46. 2 receptor. Hypertension. 33:1999;835-843.
47. 2 bradykinin receptor by ACE inhibitors. The Journal of Biological Chemistry. 275:2000;16110-16118.
48. Marcic B.M., Erdös E.G. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. Journal of Pharmacological and Experimental Therapy. 294:2000;605-612.
49. Marin-Castano M.E., Schanstra J.P., Neau E., Praddaude F., Pecher C., Ader J.L., Girolami J.P., Bascands J.L. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation. 105:2002;627-632.
50. McAllister B.S., Leeb-Lundberg F., Olson M.S. Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. American Journal of Physiology. 265:1993;C477-C484.
51. Minshall R.D., Erdös E.G., Vogel S.M. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation. American Journal of Cardiology. 80:1997;132A-136A.
52. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circulation Research. 76:1995;773-780.
53. Minshall R.D., Nedumgottil S.J., Igic R., Erdös E.G., Rabito S.F. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum. Peptides. 21:2000;1257-1264.
54. 2 receptors and angiotensin I-converting enzyme in CHO cells. Circulation Research. 81:1997;848-856.
55. Miyamoto A., Murata S., Nishio A. Role of ACE and NEP in bradykinin-induced relaxation and contraction response of isolated porcine basilar artery. Archives of Pharmacology (Naunyn Schmiedebergs). 365:2002;365-370.
56. Mombouli J.V., Ballard K.D., Vanhoutte P.M. Kininase-independent potentiation of endothelium-dependent relaxations to kinins by converting enzyme inhibitor perindoprilat. Acta Pharmacologica Sinica. 23:2002;203-207.
57. Mombouli J.V., Illiano S., Nagao T., Scott-Burden T., Vanhoutte P.M. Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium-derived relaxing and hyperpolarizing factors. Circulation Research. 71:1992;137-144.
58. Mombouli J.V., Vanhoutte P.M. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends in Pharmacological Sciences. 18:1997;252-256.
59. Nolly H., Carbini L.A., Scicli G., Carretero O.A., Scicli A.G. A local kallikrein-kinin system is present in rat hearts. Hypertension. 23:1994;919-923.
60. Nolly H.L., Lama M.C., Carretero O.A., Scicli A.G. The kallikrein-kinin system in blood vessels. Agents and Actions. 38(Suppl.):1992;1-9.
61. Pörsti I., Bara A.T., Busse R., Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. British Journal of Pharmacology. 111:1994;652-654.
62. Pörsti I., Bara A.T., Busse R., Hecker M. Corrigendum. British Journal of Pharmacology. 117:1996;231.
63. Raidoo D.M., Ramsaroop R., Naidoo S., Müller-Esterl W., Bhoola K.D. Kinin receptors in human vascular tissue: their role in atheromatous disease. Immunopharmacology. 36:1997;153-160.
64. Ren Y., Garvin J.L., Carretero O.A. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension. 39:2002;799-802.
65. Roks A.J.M., van Geel P.P., Pinto Y.M., Buikema H., Henning R.H., de Zeeuw D., van Gilst W.H. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension. 34:1999;296-301.
66. Rouleau J.L., Pfeffer M.A., Stewart D.J., Isaac D., Sestier F., Kerut E.K., Porter C.B., Proulx G., Qian C., Block A.J. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet. 356:2000;615-620.
67. Schuijt M.P., Basdew M., van Veghel R., de Vries R., Saxena P.R., Schoemaker R.G., Danser A.H.J. AT2 receptor-mediated vasodilation in the heart: effect of myocardial infarction. American Journal of Physiology. 281:2001;H2590-H2596.
68. Schuijt M.P., de Vries R., Saxena P.R., Schalekamp M.A.D.H., Danser A.H.J. Vasoconstriction is determined by intertitial rather than circulating angiotensin II. British Journal of Pharmacology. 135:2002;275-283.
69. Su J.B., Houel R., Heloire F., Barbe F., Beverelli F., Sambin L., Castaigne A., Berdeaux A., Crozatier B., Hittinger L. Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. Circulation. 101:2000;1848-1853.
70. Tallant E.A., Lu X., Weiss R.B., Chappell M.C., Ferrario C.M. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 29:1997;388-393.
71. Taylor-McCabe K.J., Ersahin C., Simmons W.H. Bradykinin metabolism in the isolated perfused rabbit heart. Journal of Hypertension. 19:2001;1295-1299.
72. Tom B., Dendorfer A., de Vries R., Saxena P.R., Danser A.H.J. Bradykinin potentiation by ACE inhibitors: a matter of metabolism. British Journal of Pharmacology. 137:2002;276-284.
73. Tom B., de Vries R., Saxena P.R., Danser A.H.J. Negative inotropic effect of bradykinin in porcine isolated atrial trabeculae: role of nitric oxide. Journal of Hypertension. 19:2001a;1289-1293.
74. Tom B., de Vries R., Saxena P.R., Danser A.H.J. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension. 38:2001b;95-99.
75. Ueda S., Masumori-Maemoto S., Ashino K., Nagahara T., Gotoh E., Umemura S., Ishii M. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man. Hypertension. 35:2000;998-1001.
76. Ueda S., Masumori-Maemoto S., Wada A., Ishii M., Brosnihan K.B., Umemura S. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. Journal of Hypertension. 19:2001;2001-2009.
77. van Kats J.P., Duncker D.J., Haitsma D.B., Schuijt M.P., Niebuur R., Stubenitsky R., Boomsma F., Schalekamp M.A.D.H., Verdouw P.D., Danser A.H.J. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation. 102:2000;1556-1563.
78. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., Godbout K., Parsons T., Baronas E., Hsieh F., Acton S., Patane M., Nichols A., Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. The Journal of Biological Chemistry. 277:2002;14838-14843.
79. Widdop R.E., Sampey D.B., Jarrott B. Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. Hypertension. 34:1999;964-968.
80. Yamada K., Iyer S.N., Chappell M.C., Ganten D., Ferrario C.M. Converting enzyme determines plasma clearance of angiotensin-(1-7). Hypertension. 32:1998;496-502.